Vernal Keratoconjunctivitis
15
1
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
40%
6 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis
Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis
Topical Immuonosuppressant Drugs in Spring Catarrh
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis
Topical Tacrolimus in Vernal Keratoconjunctivitis
Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months
Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda
Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment
Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis